What is BPC-157?
BPC-157 is a synthetic pentadecapeptide — a fifteen-amino-acid sequence — studied in research for its cytoprotective properties and for interactions with a range of signaling pathways relevant to tissue and nervous system research. The compound is designated CAS 137525-51-0, carries the molecular formula C₆₂H₉₈N₁₆O₂₂, and has a molecular weight of approximately 1419.5 g/mol. Its amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
The name is shorthand for Body Protective Compound 157, reflecting its origin as a synthetic sequence derived from a partial amino acid fragment of BPC, a protein fraction isolated from gastric juice in early characterization work. The full-length BPC protein itself is not the research compound — BPC-157 is a defined, synthetically produced peptide whose sequence was selected from that parent protein for further study. Research-grade material is supplied as a lyophilized powder intended solely for laboratory research purposes.
Within the peptide research landscape, BPC-157 occupies a distinctive position: it sits at an intersection between cytoprotective and neural-pathway research that is less common among synthetic peptides. While many neuropeptides in the research space — such as Semax or Cerebrolysin — are studied primarily through a neurotrophic signaling lens, BPC-157 enters the nervous system literature through a different route: its cytoprotective profile in tissue models prompted researchers to examine whether similar mechanisms operate in neural contexts.
What is the molecular structure of BPC-157?
BPC-157 is a linear pentadecapeptide with no disulfide bridges or cyclic constraints. The sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val encodes several structural features that have attracted research interest. The three consecutive proline residues at positions 3-4-5 create a rigid, conformationally constrained segment that resists common protease cleavage patterns; proline is an imino acid that introduces bends and limits enzymatic access in ways that other residues do not.
Published structural analyses note that this proline-dense central core is likely a key contributor to the compound's observed stability in biological research models. Short peptides are ordinarily rapid targets for peptidase activity, which limits their utility in model systems with a prolonged observation window. The structural rigidity conferred by consecutive prolines is a reasonable mechanistic explanation for BPC-157's extended persistence relative to many peptides of comparable length, though exact stability profiles are model-dependent.
The flanking glycine residues at positions 1 and 6 introduce conformational flexibility on either side of the proline core, and the charged residues — glutamate at position 2, lysine at position 7, and the two aspartate residues at positions 10-11 — contribute to the peptide's hydrophilic character. Research-grade BPC-157 is produced by solid-phase peptide synthesis and characterized by HPLC and mass spectrometry to confirm sequence identity and purity. The lyophilized form is a white to off-white powder.
What cytoprotective mechanisms has research associated with BPC-157?
Published preclinical research places BPC-157 in the cytoprotective category based on studies examining cellular and tissue responses in various injury and stress models. The mechanistic literature is concentrated in a few areas: interactions with nitric oxide signaling pathways, modulation of growth factor-associated signaling, and effects on angiogenic processes in tissue model systems.
Nitric oxide (NO) signaling research is a recurring mechanistic thread in the BPC-157 literature. Published work in preclinical models describes the compound's influence on NO pathway components, including effects on endothelial nitric oxide synthase (eNOS) activity in vascular model systems. NO signaling is of broad research relevance because the pathway is involved in vascular tone regulation, cellular stress responses, and intercellular signaling. In the context of BPC-157 research, the NO pathway is studied as one mechanistic route by which the compound's cytoprotective profile might be explained.
A second mechanistic area involves interactions with growth factor signaling. Published research describes BPC-157 associations with vascular endothelial growth factor (VEGF) signaling components in tissue models, particularly in research examining vascular and connective tissue responses. VEGF pathway interactions are studied because angiogenic processes — the formation and remodeling of vascular networks — are central to tissue repair research models where BPC-157 has been frequently investigated.
How does BPC-157 appear in nervous system and CNS research?
The nervous system and CNS injury literature is where BPC-157 research most directly intersects with Neurolevel's research focus. Published preclinical studies have examined the compound in CNS injury models, including models of traumatic brain injury, spinal cord insult, and peripheral nerve damage. This body of work does not represent the majority of the BPC-157 literature, which is weighted toward gastrointestinal and musculoskeletal tissue research, but it is a meaningful and growing subfield.
CNS injury research framing examines BPC-157 through the lens of neuroprotective mechanisms: does the compound alter cellular survival signaling, influence inflammatory cascades, or affect the vascular and glial responses that accompany neural injury in model systems? Published work describes several such associations. Preclinical CNS injury models have reported interactions with dopaminergic and serotonergic signaling pathways, making BPC-157 one of the few cytoprotective peptides studied for effects on monoamine system components in addition to its connective tissue and vascular research associations.
The dopaminergic pathway research is notable from a neuropeptide research standpoint because dopaminergic systems are the target of numerous cognitive research compounds. Published studies in preclinical models describe BPC-157 interactions with dopamine receptor-related signaling and with behavioral paradigms used to probe dopaminergic function. These studies are mechanistic preclinical investigations rather than clinical findings, and Neurolevel frames them strictly as research observations in model systems.
Serotonergic pathway associations have appeared in a parallel body of preclinical research, with published studies examining how BPC-157 affects serotonin system-related parameters in CNS models. The intersection of cytoprotective mechanisms with monoamine signaling is a research area that connects BPC-157 to broader neuroscience research questions beyond its original gastrointestinal framing, which is one reason researchers in the neuropeptide space track developments in the BPC-157 literature.
What does research describe about BPC-157 and neurotrophic factor interactions?
Published research has examined whether BPC-157's cytoprotective profile in neural models involves interactions with neurotrophic signaling pathways — the area most characteristic of compounds like Semax and Cerebrolysin. The evidence here is more limited than in the vascular or monoamine domains, but published preclinical studies in CNS injury contexts have described associations with growth factor signaling components that overlap with the neurotrophic factor space.
VEGF pathway involvement, noted above in the vascular context, is relevant here because VEGF signaling is not strictly a peripheral vascular phenomenon — published research recognizes VEGF's roles in CNS vascular biology and in the neurovascular unit, which connects vascular-neural crosstalk to broader neuropeptide research questions. Some published CNS research framing BPC-157 describes the compound's effects through this neurovascular lens: that cytoprotection in neural injury models may occur partly through vascular remodeling mechanisms in the CNS rather than through direct neurotrophic factor interactions.
Whether BPC-157 engages BDNF or NGF signaling pathways directly is not as well characterized as its NO and VEGF associations, and published research is more circumspect on this point. The honest characterization of the current literature is that BPC-157's appearance in neural research models is primarily mechanistically attributed to NO pathway modulation, monoamine system interactions, and neurovascular effects — with neurotrophic factor interactions as a peripheral and less-characterized association.
How does BPC-157's stability profile affect research design?
The structural stability associated with BPC-157's proline-rich sequence has practical implications for research design that distinguish it from more structurally labile short peptides. Published research in animal models frequently describes BPC-157 as active across multiple experimental delivery contexts, which is unusual for a peptide of its length. Most fifteen-residue linear peptides would be expected to degrade rapidly in physiological media, but the proline-dense core is thought to confer resistance to this rapid inactivation.
This stability has allowed published research to examine the compound across a wider range of model contexts than many comparable peptides, contributing to the breadth of the published literature. At the same time, it creates interpretive complexity: a compound that persists longer and distributes more broadly in model systems is harder to assign to a single pathway or mechanism than a compound that acts locally before rapid clearance. The breadth of BPC-157's published research associations — vascular, neural, musculoskeletal, gastrointestinal — likely reflects both genuine multi-pathway engagement and this extended presence in model systems.
Research design considerations include the selection of appropriate model systems and controls for distinguishing direct mechanism from secondary or systemic effects. Published research groups that examine BPC-157 in CNS contexts frequently use peripheral injury comparators and pathway-specific inhibitor studies to parse direct neural effects from indirect vascular or systemic contributions. Competent engagement with the CNS research literature requires understanding this interpretive complexity.
How does BPC-157 compare structurally to other research peptides in this category?
BPC-157's structural profile is distinctive relative to the neuropeptides that form the core of neurolevel's compound catalog. Where Semax is a heptapeptide derived from an ACTH fragment with a synthetic Pro-Gly-Pro stabilization sequence, and Cerebrolysin is a complex biological mixture of low-molecular-weight neuropeptide fractions, BPC-157 is a linear synthetic fifteen-mer with an endogenous-protein-fragment origin and an unusual proline-dense core.
The comparison is useful for framing how different structural strategies arrive at research-relevant stability and multi-system engagement. Semax achieves stability through a C-terminal proline extension on an otherwise short fragment. BPC-157 achieves stability through an embedded triple-proline motif at the center of a longer sequence. Cerebrolysin does not address individual-peptide stability in the same way because it is a mixture where each fraction has its own profile.
What connects BPC-157 to the neuropeptide research category is not its primary classification — cytoprotective is a more accurate label — but the growing body of neural and CNS research that examines how its mechanisms operate in nervous system contexts. For researchers interested in neural pathway modulation through cytoprotective mechanisms, BPC-157 represents a distinct research angle complementary to the neurotrophic signaling approach more characteristic of classical neuropeptides.
How does Neurolevel source and supply BPC-157?
Neurolevel supplies BPC-157 as a research-grade lyophilized powder characterized to a purity specification of 99% by HPLC, with mass spectrometry identity confirmation against the defined sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and the confirmed formula C₆₂H₉₈N₁₆O₂₂. A batch-specific Certificate of Analysis is included with every order, and all shipments use cold-chain packaging as standard to preserve peptide integrity in transit.
Researchers can review specifications, available sizes, and related cytoprotective and neuropeptide research compounds on the BPC-157 product page or browse the complete compound catalog. For comparison with neurotrophic signaling-focused compounds in the same research category, see the Semax research overview and the Cerebrolysin research overview. All material is intended for laboratory research use only.
This compound is a research chemical intended for laboratory and scientific research purposes only. It is not a drug, supplement, or food, and is not intended to diagnose, treat, cure, or prevent any disease. Neurolevel does not sell products intended for human use. Researchers are responsible for compliance with all applicable local, state, and federal regulations.